Successful oral desensitization to voriconazole in a patient with fungal arthritis caused by Exophiala sp.
case report
DOI:
https://doi.org/10.47456/rbps.v26i1.51201Keywords:
Voriconazole, Desensitization Immunologic, Exophiala, Infectious arthritisAbstract
Introduction: The impossibility of treatment due to allergy to antimicrobials is a major limitation in the treatment of infections. In these cases, desensitization becomes an alternative, especially when dealing with etiological agents with few treatment options available. Methods: Report of a successful case of desensitization to voriconazole, orally. Case report: We report the case of a 61-year-old man with systemic lupus erythematosus who developed fungal arthritis caused by exophiala sp., during treatment with voriconazole he developed erythematous skin lesions. With the discontinuation of voriconazole, the lesions improved, however, the change to itraconazole was not effective in treating the infection. Conclusion: Therefore, it was decided to carry out desensitization to voriconazole, which allowed a gradual increase in the dose of the antifungal with good tolerance to the treatment.
Downloads
References
Greer ND. Voriconazole: the newest triazole antifungal agent. Proc (Bayl Univ Med Cent). 2003 Apr;16(2):241-8.
Eiden C, Peyrière H, Cociglio M, Djezzar S, Hansel S, Blayac JP, Hillaire-Buys D; Network of the French Pharmacovigilance Centers. Adverse effects of voriconazole: analysis of the French Pharmacovigilance Database. Ann Pharmacother. 2007 May;41(5):755-63.
Rossini R, Iorio A, Pozzi R, Bianco M, Musumeci G, Leonardi S, Lettieri C, Bossi I, Colombo P, Rigattieri S, Dossena C, Anzuini A, Capodanno D, Senni M, Angiolillo DJ. Aspirin Desensitization in Patients With Coronary Artery Disease: Results of the Multicenter ADAPTED Registry (Aspirin Desensitization in Patients With Coronary Artery Disease). Circ Cardiovasc Interv. 2017 Feb;10(2):e004368.
Tal Y, Maoz Segal R, Langevitz P, Kivity S, Darnizki Z, Agmon-Levin N. Hydroxychloroquine desensitization, an effective method to overcome hypersensitivity-a multicenter experience. Lupus. 2018 Apr;27(5):703-707.
Zwiener R, Marino G, Danna MM, Tamara B, Matias TB. Successful desensitization to voriconazole. J Allergy Clin Immunol 2013;131:AB166.
Jean T, Kwong K. Successful desensitization of voriconazole in na immunosuppressed pediatric patient. J Allergy Clin Immunol Pract. 2015 Jul-Aug;3(4):637-8.
Usuda D, Higashikawa T, Hotchi Y, Usami K, Shimozawa S, Tokunaga S, Osugi I, Katou R, Ito S, Yoshizawa T, Asako S, Mishima K, Kondo A, Mizuno K, Takami H, Komatsu T, Oba J, Nomura T, Sugita M. Exophiala dermatitidis. World J Clin Cases 2021; 9(27): 7963- 72.
Narumoto O, Suzuki J, Takeda K, Tamura A, Nagai H, Matsui H. Rechallenge of voriconazole successfully tolerated after hepatic toxicity. Respir Med Case Rep. 2020 Aug 13;31:101191.
Tal Y, Maoz Segal R, Langevitz P, Kivity S, Darnizki Z, Agmon-Levin N. Hydroxychloroquine desensitization, an effective method to overcome hypersensitivity-a multicenter experience. Lupus. 2018 Apr;27(5):703-707.
Rossini R, Iorio A, Pozzi R, Bianco M, Musumeci G, Leonardi S, Lettieri C, Bossi I, Colombo P, Rigattieri S, Dossena C, Anzuini A, Capodanno D, Senni M, Angiolillo DJ. Aspirin Desensitization in Patients With Coronary Artery Disease: Results of the Multicenter ADAPTED Registry (Aspirin Desensitization in Patients With Coronary Artery Disease). Circ Cardiovasc Interv. 2017 Feb;10(2):e004368.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Brazilian Journal of Health Research
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The Revista Brasileira de Pesquisa em Saúde (RBPS) adopts the CC BY 4.0 license, which means that authors retain the copyright of the works they submit to the journal. Authors are responsible for declaring that their contribution is an original manuscript, that it has not been previously published, and that it is not under simultaneous review by another scientific journal. Upon submitting the manuscript, authors grant RBPS the exclusive right of first publication, subject to peer review.
Authors are permitted to enter into additional contracts for the non-exclusive distribution of the version published by RBPS (for example, in institutional repositories or as a book chapter), provided that due acknowledgment of authorship and of initial publication by RBPS is given. Authors are also encouraged to make their work available online (for example, in institutional repositories or on their personal pages) after its initial publication in the journal, with due acknowledgment of authorship and of the original publication by RBPS.
Accordingly, under the CC BY 4.0 license, readers have the right to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially;
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The licensor cannot revoke these freedoms as long as you follow the license terms. Under the following terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
